Mohr and associates (2017) noted that mixed UI (MUI), defined as mixed symptoms of SUI and OAB, is a difficult entity if conservative treatment has failed. Cure rates are low compared with SUI, particularly the OAB component, may deteriorate after sling insertion. Bulking agents pose an appealing alternative for the treatment of MUI. They have shown beneficial effect in small case studies, but larger series are lacking. In a prospective study, these investigators examined the safety and efficacy profile of Bulkamid in female patients with MUI. A total of 154 women with MUI symptoms (components of SUI/OAB within the limits of 60 to 40 % either way) received bulking therapy with Bulkamid. Patients were followed-up 3 months post-operatively. Primary outcome was the domain Incontinence impact on the KHQ; secondary outcomes were the other KHQ domains, visual analog scale (VAS), and International Continence Society (ICS) standardized pad weight test as objective measurement of incontinence. Statistically significant improvements were found for all KHQ domains, pad weight test, and the VAS before and after bulking; overall complication rate was 13 %. The authors concluded that the findings of this study showed improvement in MUI after bulking therapy according to both subjective and objective outcomes. These investigators could advocate bulking therapy for treating MUI, as it is simple and safe and showed both objective and subjective improvement and relief. They stated that long-term results (up to 1 year) are awaited.